Video

The Long-Term Impact of Biosimilars on Specialty Pharmacy

Author(s):

Lauren Santye, Assistant Editor

Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.

Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.

Related Videos
Related Content
US FDA logo on smartphone -- Image credit: Luciano Luppa | stock.adobe.com
April 30th 2025

FDA Approves Nipocalimab-Aahu to Treat Patients With Generalized Myasthenia Gravis

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Assuring clients are informed. Shot of a young pharmacist helping an elderly customer at the prescription counter.
April 29th 2025

Asembia AXS25: Pharmacists Continue to Expand Clinical, Collaborative Role in Health Care

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Two African American pharmacists working in drugstore at hospital pharmacy | Image Credit: © AS Photo Family - stock.adobe.com
April 29th 2025

Asembia AXS25: Balancing Innovation With Affordability Crucial for Sustainable Rare Disease Economic Models

Luke Halpern, Assistant Editor
Portrait of a male pharmacist working at the counter in pharmacy | Image Credit: © Zamrznuti tonovi - stock.adobe.com
April 29th 2025

Asembia AXS25: Community Pharmacists Can Optimize Specialty Pharmacy Care

Luke Halpern, Assistant Editor